Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + salmeterol (Teva Pharmaceutical Industries Ltd.)
- Development stage
- Phase 4
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AirDuo (marketed as AirDuo RespiClick and AirDuo Digihaler) is an FDA-approved fixed-dose combination of fluticasone propionate and salmeterol xinafoate. Developed by Teva and its subsidiary Actavis Laboratories, it is indicated for the maintenance treatment of asthma in patients aged 12 years and older. Fluticasone propionate is an inhaled corticosteroid (ICS) that targets the glucocorticoid receptor to suppress inflammatory processes in the lungs, while salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta-2 adrenergic receptors to relax airway smooth muscle and improve lung function. The drug is delivered via a breath-activated dry powder inhaler and is administered twice daily. It is not indicated for the relief of acute bronchospasm.
- Brand names
- AirDuoAirDuo DigihalerAirDuo RespiClick
- Other names
- fluticasone propionate + salmeterolfluticasone propionate + salmeterol xinafoatefluticasone propionate/salmeterol xinafoatefluticasone/salmeterolsalmeterol xinafoate + fluticasone propionate
02
Targets
ADRB1 (β1)ADRB2 (β2)ADRB3 (β3)GR (Glucocorticoid receptor)Kv1 (Voltage-gated potassium channel subfamily A)
Beyond the preview
Go deeper on fluticasone propionate + salmeterol (Teva Pharmaceutical Industries Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + salmeterol (Teva Pharmaceutical Industries Ltd.).